310 related articles for article (PubMed ID: 26982012)
21. Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis.
Hahn L; Beggs A; Wahaib K; Kodali L; Kirkwood V
Am J Health Syst Pharm; 2015 Aug; 72(15):1271-8. PubMed ID: 26195652
[TBL] [Abstract][Full Text] [Related]
22. Natalizumab for induction of remission in Crohn's disease.
Macdonald JK; McDonald JW
Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
[TBL] [Abstract][Full Text] [Related]
23. Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing.
D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
Immunotherapy; 2019 May; 11(7):565-575. PubMed ID: 30860423
[TBL] [Abstract][Full Text] [Related]
24. Vedolizumab for the treatment of moderately to severely active ulcerative colitis.
Dulai PS; Mosli M; Khanna R; Levesque BG; Sandborn WJ; Feagan BG
Pharmacotherapy; 2015 Apr; 35(4):412-23. PubMed ID: 25884529
[TBL] [Abstract][Full Text] [Related]
25. Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease.
Becker E; Schramm S; Binder MT; Allner C; Wiendl M; Neufert C; Atreya I; Neurath M; Zundler S
J Vis Exp; 2018 Sep; (139):. PubMed ID: 30295649
[TBL] [Abstract][Full Text] [Related]
26. Vedolizumab for the treatment of ulcerative colitis.
Rietdijk ST; D'Haens GR
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):423-30. PubMed ID: 24802046
[TBL] [Abstract][Full Text] [Related]
27. PF-00547659 for the treatment of Crohn's disease and ulcerative colitis.
Allocca M; Gilardi D; Fiorino G; Furfaro F; Argollo M; Peyrin-Biroulet L; Danese S
Expert Opin Investig Drugs; 2018 Jul; 27(7):623-629. PubMed ID: 29985060
[TBL] [Abstract][Full Text] [Related]
28. Vedolizumab for the treatment of inflammatory bowel disease.
Haddley K
Drugs Today (Barc); 2014 Apr; 50(4):309-19. PubMed ID: 24918648
[TBL] [Abstract][Full Text] [Related]
29. Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
Panés J; Salas A
J Crohns Colitis; 2018 Aug; 12(suppl_2):S633-S640. PubMed ID: 30137311
[TBL] [Abstract][Full Text] [Related]
30. Emerging Therapies for Inflammatory Bowel Diseases.
Khanna R; Feagan BG
Dig Dis; 2016; 34 Suppl 1():67-73. PubMed ID: 27548692
[TBL] [Abstract][Full Text] [Related]
31. The safety of vedolizumab for the treatment of ulcerative colitis.
Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
[TBL] [Abstract][Full Text] [Related]
32. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
[TBL] [Abstract][Full Text] [Related]
33. Controlling leukocyte trafficking in IBD.
Veny M; Fernández-Clotet A; Panés J
Pharmacol Res; 2020 Sep; 159():105050. PubMed ID: 32598943
[TBL] [Abstract][Full Text] [Related]
34. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease.
McLean LP; Shea-Donohue T; Cross RK
Immunotherapy; 2012 Sep; 4(9):883-98. PubMed ID: 23046232
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.
Yajnik V; Khan N; Dubinsky M; Axler J; James A; Abhyankar B; Lasch K
Adv Ther; 2017 Feb; 34(2):542-559. PubMed ID: 28070861
[TBL] [Abstract][Full Text] [Related]
36. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG
Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427
[TBL] [Abstract][Full Text] [Related]
37. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
[TBL] [Abstract][Full Text] [Related]
38. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases.
Luzentales-Simpson M; Pang YCF; Zhang A; Sousa JA; Sly LM
Front Cell Dev Biol; 2021; 9():612830. PubMed ID: 33614645
[TBL] [Abstract][Full Text] [Related]
39. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
Danese S; Panés J
Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
[TBL] [Abstract][Full Text] [Related]
40. New biologic therapeutics for ulcerative colitis and Crohn's disease.
Mozaffari S; Nikfar S; Abdolghaffari AH; Abdollahi M
Expert Opin Biol Ther; 2014 May; 14(5):583-600. PubMed ID: 24502344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
